Implementation of Guidance in Primary Care (NICE, ADA, EASD)- Working together to influence change

Invokana^®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.

Prescribing information can be found next to the watch the webinar buttons.
These recordings are intended for UK Healthcare Professionals only. Please ensure members of the public can't see or hear the content

Implementation of Guidance in Primary Care (NICE, ADA, EASD)- Working together to influence change

Description:
This video is part of The Many Faces of Diabetes webinar titled “Glycaemic control and renal and cardiovascular outcomes in type 2 diabetes”. Professor Partha Kar’s presentation focuses on what the guidelines say about the treatment and management of type 2 diabetes, new additions and how to consider them in your local practice.
Presented at The Many Faces of Diabetes national webinar on 13th July 2023.
Duration 17 minutes

Useful Resources

Professor Kar has been a Consultant in Diabetes & Endocrinology at Portsmouth Hospitals NHS Trust since 2008. He has been the Clinical Director of Diabetes from 2009-2015, being part of a multiple national award-winning department (Health Services Journal Awards / British Medical Journal Awards) due to its services and care provided. He is also the co-creator of TAD talks (Talking About Diabetes) and the type 1 diabetes comic (“Origins”) while also involved in setting up a type 1 diabetes information portal, T1resources.uk. Additionally, Professor Kar is Associate National Clinical Director of Diabetes with NHS England leading on digital innovation.

PP-ENDO-UK-140 September 2023